November 30, 2017 Pharmacosmos Introduces Pharmaceutical Quality DEAE-Dextran

The first DEAE-Dextran with Certificate of GMP compliance


Pharmacosmos, a world leader in developing and producing carbohydrates for pharmaceutical applications, is the first company to introduce DEAE-Dextran in a Pharmaceutical Quality.

DEAE-Dextran is a polycationic derivative of dextran. Its commercial applications include use as a vaccine adjuvant, a transfection agent for gene therapy, and as an ingredient in cholesterol lowering products.

"The introduction of our DEAE-Dextran Pharmaceutical Quality is an important addition to our portfolio of carbohydrates produced according to GMP. This will enable our pharmaceutical customers to continue to expand their use of DEAE-Dextran while meeting increasingly high regulatory requirements" says Dr Lars Christensen, President and CEO at Pharmacosmos.

Pharmacosmos is the first company to offer GMP certified DEAE-Dextran. The certificate of GMP compliance has been issued by the Danish Medicines Agency. Pharmacosmos is also the only manufacturer of dextran that holds certificates from the US FDA and the European Directorate for the Quality of Medicines (EDQM).

For additional information on the new pharmaceutical quality DEAE-Dextran please visit www.dextran.com

Contact

Media: Tobias Christensen, VP Corporate Development & Strategy, E: tsc@pharmacosmos.com, T: +45 5948 5959
Customer inquiries: Anne-Marie Oerkild, International Sales and Business Director, Carbohydrates, E: amo@pharmacosmos.com or dextran@pharmacosmos.com, T: +45 5948 5959

About Pharmacosmos


Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.

A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.

Pharmacosmos has subsidiaries in US, UK, Ireland, Germany, Sweden and Norway and its products are marketed in more than 80 countries around the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.

Pharmacosmos